Intercept Pharmaceuticals Inc

Latest Intercept Pharmaceuticals Inc News and Updates

  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///drug _
    Healthcare

    If You Own Intercept Stock, Should You Sell It Now?

    On Monday, Intercept Pharmaceuticals (NASDAQ:ICPT) stock lost 39.7% and closed at $46.70 with a market cap of $1.54 billion.

    By Ambrish Shah
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///ICPT_
    Company & Industry Overviews

    An In- Depth Look at Intercept Pharmaceuticals’ Ocaliva

    Intercept Pharmaceuticals is evaluating a development strategy for Ocaliva in other indications.

    By Kenneth Smith
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
  • Company & Industry Overviews

    What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?

    The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are XBI’s Holdings’ Moving Averages Trending?

    On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals Doing with IONIS-TTR?

    In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.